Allergan CEO Brent Saunders, who once called Big Pharma's perceived need for drug discovery "a fallacy," has come around on early-stage research, a change in tone that happens to coincide with Pfizer's stated interest in buying his company.
Transcriptic has added CRISPR gene editing to the list of services provided by its robotic laboratory. The service expansion is being supported by Desktop Genetics, a developer of gene-editing software that is making its CRISPR library design algorithms available to Transcriptic.
Ginkgo Bioworks and Twist Bioscience have struck a deal to cement their status as two of the hottest players in the new wave of biotech startups. The one-year agreement sees Twist sign up to supply Ginkgo with 100 million base pairs of synthetic DNA.
A surgically implanted artificial kidney under development at the University of California, San Francisco, has been accepted into the FDA's Expedited Access Pathway for "breakthrough" technologies that debuted just 6 months ago.
Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.
Allergan expanded its pipeline with a $50 million deal to bring in a late-stage treatment for dry eye as the company works to reaffirm its commitment to R&D in the face of industrywide scrutiny.
Cue the Medtronic-Covidien layoffs. Medtronic is cutting 150 jobs in Ireland, months after closing its megadeal with Covidien and shifting its domicile to the country to enjoy the benefits of a lower tax rate.
After Sanofi's sizable investment into its dengue vaccine program, new company CEO Olivier Brandicourt said on the Q3 call that the French pharma expects its first license to market the vaccine by year end.
Seeking to throw support into a field that has seen recent scientific advancements, the European Commission is stepping up with funding to form the European AIDS Vaccine Initiative. The effort will set out to develop protective and therapeutic HIV vaccines by bringing together experts from 22 institutions, both public and private.
GlaxoSmithKline has struck a deal to trial its anti-OX40 monoclonal antibody in combination with Merck's Keytruda. The Phase I study is part of a slate of programs that GSK is hoping will support filings for up to 20 new drug approvals in the coming years, the success rate of which will go a long way to deciding whether the company can bounce back from its recent travails.